SarcoCare 260g
Orthoplex
Orthoplex SarcoCare is a specialist formulation designed for practitioners in clinical practice. Muscle strength and muscle mass decline as a consequence of ageing and lack of physical activity. Short periods of bed rest significantly accelerate this decline. Taking steps to maintain muscle health is important for adults of all ages given our general wellbeing and personal independence are impacted by our strength.
Orthoplex SarcoCare is a purely nutritional formula combining the key nutrient beta-hydroxybetamethylbutyrate (HMB) with creatine in a delicious chocolate-flavoured pea protein for improved compliance.
Gluten FreeEgg FreeDairy FreeSoy Protein FreeVeganVegetarian-
Product Details
Pack Size
260g
Storage
Store below 25°C in a cool, dry place away from direct sunlight.
Indications
Supports muscle health and function
Maintains muscle mass in ageing individuals
Supports muscle strength during resistance training
Excipients
Manufacturing Excipients: Cocoa powder, natural dark chocolate powder flavour, silicon dioxide, steviol glycosides. Incidental Excipients: Nil.
Warning
If symptoms persist, seek the advice of a healthcare professional. Contains sulfites. Contains sodium 223mg per 26g dose.
Mix 2 scoops (1 level included scoop contains approx. 13g) into milk or water and consume immediately. Take once or twice daily, or as recommended by your registered healthcare practitioner.
| Calcium beta-hydroxy-beta-methylbutyrate monohydrate (Calcium HMB) | 1.41g |
| equiv. Calcium | 206.0mg |
| Creatine monohydrate | 2.5g |
| From Pisum sativum seed dry | 15.0g |
| equiv. From Pisum sativum seed dry | 150.0g |
| equiv. Pea protein | 10.8g |
Calcium seems to reduce levels of elvitegravir.<br> Advise patients to take elvitegravir either 2 hours before or 2 hours after taking calcium supplements. Pharmacokinetic research suggests that taking calcium along with elvitegravir can reduce blood levels of elvitegravir through chelation (94166).
Calcium seems to reduce levels of dolutegravir. <br> Advise patients to take dolutegravir either 2 hours before or 6 hours after taking calcium supplements. Pharmacokinetic research suggests that taking calcium carbonate 1200 mg concomitantly with dolutegravir 50 mg reduces plasma levels of dolutegravir by almost 40%. Calcium appears to decrease levels of dolutegravir through chelation (93578).
Co-administration of intravenous calcium and ceftriaxone can result in precipitation of a ceftriaxone-calcium salt in the lungs and kidneys.<br> Avoid administering intravenous calcium in any form, such as parenteral nutrition or Lactated Ringers, within 48 hours of intravenous ceftriaxone. Case reports in neonates show that administering intravenous ceftriaxone and calcium can result in precipitation of a ceftriaxone-calcium salt in the lungs and kidneys. In several cases, neonates have died as a result of this interaction (15794,21632). So far there are no reports in adults; however, there is still concern that this interaction might occur in adults.
15794
Rocephin (ceftriaxone) and calcium interaction. Pharmacist's Letter / Prescriber's Letter 2007;23(10):231005.
21632
Bradley JS, Wassel RT, Lee L, et al. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics. 2009;123(4):e609-13.
Using intravenous calcium with digoxin might increase the risk of fatal cardiac arrhythmias. <br> Hypercalcemia increases the risk of fatal cardiac arrhythmias with digoxin (12940). However, one retrospective analysis of clinical data suggests that intravenous calcium does not increase the risk of dysrhythmias or mortality in patients receiving digoxin (38960).
Taking calcium along with thiazides might increase the risk of hypercalcemia and renal failure. <br> Thiazides reduce calcium excretion by the kidneys (1902). Using thiazides along with moderately large amounts of calcium carbonate increases the risk of milk-alkali syndrome (hypercalcemia, metabolic alkalosis, renal failure). Patients may need to have their serum calcium levels and/or parathyroid function monitored regularly.
Theoretically, calcium may reduce the therapeutic effects of verapamil. <br> Hypercalcemia can reduce the effectiveness of verapamil in atrial fibrillation (10574). Theoretically, use of calcium supplements may increase this risk of hypercalcemia and reduce the effectiveness of verapamil.
Theoretically, calcium may reduce the therapeutic effects of diltiazem. <br> Hypercalcemia can reduce the effectiveness of verapamil in atrial fibrillation (10574). Theoretically, calcium might increase this risk of hypercalcemia and reduce the effectiveness of diltiazem.
Calcium reduces the absorption of bisphosphonates. <br> Advise patients to take bisphosphonates at least 30 minutes before calcium, but preferably at a different time of day. Calcium supplements decrease absorption of bisphosphonates (12937).
Calcium seems to reduce the absorption of tetracycline antibiotics. <br> Advise patients to take oral tetracyclines at least 2 hours before, or 4-6 hours after calcium supplements. Taking calcium at the same time as oral tetracyclines can reduce tetracycline absorption. Calcium binds to tetracyclines in the gut (1843).
Calcium seems to reduce the absorption of quinolone antibiotics.<br> Advise patients to take oral quinolones at least 2 hours before or 4-6 hours after calcium supplements or calcium-fortified foods. Taking calcium at the same time as oral quinolones can reduce quinolone absorption. Calcium binds to quinolones in the gut (4412,10339,21638,38570).
4412
Murry JJ, Healy MD. Drug-mineral interactions: a new responsibility for the hospital dietician. J Am Diet Assoc 1991;91:66-73.
10339
Pletz MW, Petzold P, Allen A, et al. Effect of calcium carbonate on bioavailability of orally administered gemifloxacin. Antimicrob Agents Chemother 2003;47:2158-60..
21638
Kays MB, Overholser BR, Mueller BA, et al. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis. 2003;42(6):1253-9.
38570
Neuhofel, A. L., Wilton, J. H., Victory, J. M., Hejmanowsk, L. G., and Amsden, G. W. Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction. J Clin Pharmacol. 2002;42(4):461-466.
Taking calcipotriene with calcium might increase the risk for hypercalcemia. <br> Calcipotriene is a vitamin D analog used topically for psoriasis. It can be absorbed in sufficient amounts to cause systemic effects, including hypercalcemia (12938). Theoretically, combining calcipotriene with calcium supplements might increase the risk of hypercalcemia.
Calcium citrate might increase aluminum absorption and toxicity. Other types of calcium do not increase aluminum absorption. <br> Calcium citrate can increase the absorption of aluminum when taken with aluminum hydroxide. The increase in aluminum levels may become toxic, particularly in individuals with kidney disease (21631). However, the effect of calcium citrate on aluminum absorption is due to the citrate anion rather than calcium cation. Calcium acetate does not appear to increase aluminum absorption (93006).
21631
Coburn JW, Mischel MG, Goodman WG, et al. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis. 1991;17(6):708-11.
93006
Nolan CR, Califano JR, Butzin CA. Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int. 1990;38(5):937-41.
Theoretically, concomitant use of calcium and lithium may increase this risk of hypercalcemia. <br> Clinical research suggests that long-term use of lithium may cause hypercalcemia in 10% to 60% of patients (38953). Theoretically, concomitant use of lithium and calcium supplements may further increase this risk.
Calcium may reduce levels of raltegravir. <br> Pharmacokinetic research shows that taking a single dose of calcium carbonate 3000 mg along with raltegravir 400 mg twice daily modestly decreases the mean area under the curve of raltegravir, but the decrease does not necessitate a dose adjustment of raltegravir (94164). However, a case of elevated HIV-1 RNA levels and documented resistance to raltegravir has been reported for a patient taking calcium carbonate 1 gram three times daily plus vitamin D3 (cholecalciferol) 400 IU three times daily in combination with raltegravir 400 mg twice daily for 11 months. It is thought that calcium reduced raltegravir levels by chelation, leading to treatment failure (94165).
94164
Insentress [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2014.
94165
Roberts JL, Kiser JJ, Hindman JT, Meditz AL. Virologic failure with a raltegravir-containing antiretroviral regimen and concomitant calcium administration. Pharmacotherapy 2011;31(10):298e-302e.
Calcium seems to reduce the absorption of sotalol. <br> Advise patients to separate doses by at least 2 hours before or 4-6 hours after calcium. Calcium appears to reduce the absorption of sotalol, probably by forming insoluble complexes (10018).
Calcium seems to reduce the absorption and effectiveness of levothyroxine. <br> Advise patients to take levothyroxine and calcium supplements at least 4 hours apart. Calcium reduces levothyroxine absorption, probably by forming insoluble complexes (5082). Calcium carbonate supplements reduce effectiveness of levothyroxine in patients with hypothyroidism (5081,5082,6137).
5081
Butner LE, Fulco PP, Feldman G, et al. Calcium carbonate-induced hypothyroidism. Ann Intern Med 2000:132:595.
5082
Schneyer CR. Calcium carbonate and reduction of levothyroxine efficacy. JAMA 1998;279:750.
6137
Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA 2000;283:2822-5.
Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.<br> Intravenous calcium is used to decrease the effects of calcium channel blockers in the management of overdose. Intravenous calcium gluconate has been used before intravenous verapamil (Isoptin) to prevent or reduce the hypotensive effects without affecting the antiarrhythmic effects (6124). But there is no evidence that dietary or supplemental calcium when taken orally interacts with calcium channel blockers (12939,12947).
6124
Moser LR, Smythe MA, Tisdale JE. The use of calcium salts in the prevention and management of verapamil-induced hypotension. Ann Pharmacother 2000;34:622-9.
12939
Gueguen L, Pointillart A. The bioavailability of dietary calcium. J Am Coll Nutr 2000;19:119s-136s.
12947
Bania TC, Blaufeux B, Hughes S, et al. Calcium and digoxin vs. calcium alone for severe verapamil toxicity. Acad Emerg Med 2000;7:1089-96.
Full Reference List
Rating System Description
Do not use combination; contraindicated; strongly discourage patients from using this combination; a serious adverse outcome could occur.
Use cautiously or avoid combination; warn patients that a significant interaticon or adverse outcome could occur.
Be aware that there is a chance of an interaction; advise patients to watch for warning signs of a potential interaction.
Likelihood of Occurrence
Likely: Well‑controlled human studies have demonstrated existence of this interaction.
Probable: Interaction has not been documented in well‑controlled studies, however interaction has been demonstrated in human studies or in controlled animal studies plus multiple case reports.
Possible: Interaction has been documented in animal or in vitro research, or interaction has been documented in humans but is limited to case reports or conflicting clinical research.
Unlikely: Interaction has been demonstrated in animal or in vitro research but has been shown not to occur in humans.
Severity
High: Life threatening or requires medical intervention to prevent a serious adverse event.
Moderate: Worsened clinical status and/or requires medication adjustment.
Mild: May cause minor clinical side effects. Unlikely to require medication adjustment.
Insignificant: Drug or supplement levels may be affected but will not cause clinical effects.
Level of Evidence
A: High-quality randomized controlled trial(RCT).
A: High-quality meta-analysis (quantitative systematic review)
B: Nonrandomized clinical trial
B: Nonquantitative systematic review
B: Lower quality RCT
B: Clinical cohort study
B: Case-control study
B: Historical control
B: Epidemoilogic study
C: Consensus
C: Expert opinion
D: Acecdotal evidence
D: In vitro or animal study
D: Theoretical based on pharmacology
© 2019 TRC is a registered trademark of Therapeutic Research Center.
TRC and all associated names and service marks including TRC are restricted and reserved for Therapeutic Research Center use.
Natural Medicines™ and associated Natural Medicines product marks are trademarks of Therapeutic Research Center.
Disclaimer: This information on interactions is licensed from the TRC Natural Medicines Database. Neither Bio Concepts nor TRC are providing medical, clinical or other advice and nothing should be interpreted as constituting such advice. Currently this does not check for drug-drug or supplementsupplement interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgement is necessary.
|
File
|
View |
Contraindications*:
Pregnancy & Lactation: Not suitable.
*Information taken from Natural Medicines Database regarding “Major” contraindications related to active ingredients only and accurate as of September 2022. Please refer to Natural Medicines Database for more information.